Abstract: The invention relates to a process for the preparation of dimeric contrast agents for use in Magnetic resonance Imaging (MRI), in particular [?-[1-[bis[2-(hydroxy-?O)-3-[4,7,10-tris[(carboxy-?O)methyl]-1,4,7,10-tetraazacyclododec-1-yl-?N1,?N4,?N7,?N10]propyl]amino]-1-deoxy-D-glucitolate(6-)]]di-gadolinium complex, which includes preparation steps carried out one-pot (without isolation of the obtained intermediate) and precipitation of at least part of free gadolinium metal ions in excess.

Abstract: The present invention relates to a process for the manufacturing of a mixture comprising the intermediate 1-[bis[2-hydroxy-3-[4,7,10-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1,4,7,10-tetraazacyclododec-1-yl]propyl]amino]-1-deoxy-D-glucitol. Such intermediate is useful for the synthesis of the dimeric gadolinium complex [?-[1-[bis[2-(hydroxy-?O)-3-[4,7,10-tris[(carboxy-?O)methyl]-1,4,7,10-tetraazacyclododec-1-yl-?N1,?N4,?N7,?N10]propyl]amino]-1-deoxy-D-glucitolate(6-)]]digadolinium complex, which can be employed as a contrast agent in the field of diagnostic imaging, and in particular of Magnetic Resonance Imaging (MRI).

Abstract: The invention relates to a process for the preparation of the gadolinium dimeric contrast agent [p-[1-[bis[2-(hydroxy-KO)-3-[4,7,10-tris[(carboxy-KO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-K/V1,K/V4,K/V7,K/V10]propyl]amino]-1-deoxy-D-glucitolato(6-)]]di-gadolinium complex. Such process includes preparation steps carried out one-pot and without isolation of the obtained intermediates. The gadolinium dimeric contrast agent can be for use in diagnostic imaging, in particular in Magnetic resonance Imaging (MRI).

Abstract: The invention relates to a process for the manufacturing of a solution of a dimeric C gadolinium complex, such as [?-[1-[bis[2-(hydroxy-xO)-3-[4,7,10-tris[(carboxy-xO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-?N1,?N4, ?N7,?N10]propyl]amino]-1-deoxy-D-glucitolate(6-)]]digadoliniumcomplex, which is useful in the field of diagnostic imaging and of contrast agents in Magnetic Resonance Imaging (MRI), comprising the steps of precipitating a portion of free gadolinium metal ions by means of a precipitating agent. The invention further relates to a process for isolating the dimeric gadolinium complex from said solution, and to the solution and the isolated dimeric gadolinium complex obtainable by such processes.

Abstract: The invention relates to a process for the preparation of dimeric contrast agents for use in Magnetic resonance Imaging (MRI), in particular [?-[1-[bis[2-(hydroxy-?O)-3-[4,7,10-tris[(carboxy-?O)methyl]-1,4,7,10-tetraazacyclododec-1-yl-?N1,?N4,?N7,?N10]propyl]amino]-1-deoxy-D-glucitolate(6-)]]di-gadolinium complex, which includes preparation steps carried out one-pot (without isolation of the obtained intermediate) and precipitation of at least part of free gadolinium metal ions in excess.

Abstract: The invention relates to a process for the preparation of dimeric contrast agents for use in Magnetic resonance Imaging (MRI), in particular [?-[1-[bis[2-(hydroxy-kO)-3-[4,7,10-tris[(carboxy-kO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-kN1,kN4,kN7,kN10]propyl]amino]-1-deoxy-D-glucitolato(6-)]]di-gadolinium complex, which includes preparation steps carried out one-pot and without isolation of the obtained intermediate.

Abstract: The invention relates to a process for the recovery and recycling of the iodine from aqueous solutions comprising iodine-comprising aromatic compounds in which the iodine contained in said aromatic compounds is directly converted into molecular iodine at a pH lower than 1, in the absence of a catalyst.

Abstract: The invention relates to a process for the one-step preparation and isolation of a protected DO3A such as DO3A-tri-tert-butyl ester as a solid salt.

Abstract: The invention relates to a process for the recovery and recycling of the iodine from aqueous solutions comprising iodine-comprising aromatic compounds in which the iodine contained in said aromatic compounds is directly converted into molecular iodine at a pH lower than 1, in the absence of a catalyst.

Abstract: The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chlorosulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives.

Abstract: The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chlorosulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives.

Abstract: The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chloro-sulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives.

Abstract: The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chlorosulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives.

Abstract: The present invention generally refers to a process for the preparation of L-thyroxine derivatives. More in particular, the present invention relates to a iodination reaction of an aromatic derivative with an appropriate iodinating agent, so to afford the related iodinated compound as disodium salt, which may represent a useful intermediate for the synthesis of the L-thyroxine mono-sodium salt, and the free form thereof.

Abstract: The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chloro-sulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives.

Abstract: The present invention generally refers to a process for the preparation of L-thyroxine derivatives. More in particular, the present invention relates to a iodination reaction of an aromatic derivative with an appropriate iodinating agent, so to afford the related iodinated compound as disodium salt, which may represent a useful intermediate for the synthesis of the L-thyroxine mono-sodium salt, and the free form thereof.

Abstract: The present invention relates to the preparation of alkyl-ureas, starting from O,S-dimethyl dithiocarbonate, which provides the following steps: A) causing the O,S-dimethyl dithiocarbonate to react with a primary amine of general formula R1NH2 in order to obtain an O-methyl thiocarbamate; B) isomerising the O-methyl thiocarbamate in order to obtain an S-methyl thiocarbamate; C) causing the S-methyl thiocarbamate with a compound of general formula R′R″NH, wherein R′ and R″ may be equal or different one in respect of the other and of R1 and may be H, R2 or R3, in order to obtain one of the alkyl-ureas of formula (4), (5) or (6).